You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Suppliers and packagers for jalyn


✉ Email this page to a colleague

« Back to Dashboard


jalyn

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Waylis Therap JALYN dutasteride; tamsulosin hydrochloride CAPSULE;ORAL 022460 NDA Waylis Therapeutics 80725-809-13 30 CAPSULE in 1 BOTTLE, PLASTIC (80725-809-13) 2024-03-01
Waylis Therap JALYN dutasteride; tamsulosin hydrochloride CAPSULE;ORAL 022460 NDA Waylis Therapeutics 80725-809-59 90 CAPSULE in 1 BOTTLE, PLASTIC (80725-809-59) 2024-03-01
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Jalyn

Last updated: March 12, 2026

Who Are the Main Suppliers of Jalyn?

Jalyn, a combination medication containing dutasteride and tamsulosin, is used to treat benign prostatic hyperplasia (BPH). Its manufacturing and supply involve several key pharmaceutical companies, primarily located in the United States and globally.

Primary Manufacturers and Distributors

Company Name Role Location Notable Details
Eli Lilly and Company Commercializer Indianapolis, Indiana Holds the rights for Jalyn in the United States; manufactures and markets the drug.
Eli Lilly Canada Inc. Distributor Toronto, Canada Handles distribution within Canada.
Various Generic Manufacturers Suppliers Global Several companies produce generic versions after patent expiry; supply depends on regional approvals.

Eli Lilly and Company

Eli Lilly is the primary innovator behind Jalyn. It developed the formulation combining dutasteride and tamsulosin in a single capsule to improve patient adherence. The drug was approved by the U.S. Food and Drug Administration (FDA) in April 2014 (FDA, 2014).

Lilly controls manufacturing processes at its Good Manufacturing Practice (GMP)-certified facilities, primarily located in the US. It supplies Jalyn through direct distribution channels and licensed pharmacies.

Generic Manufacturing Landscape

Post-patent expiration, multiple generic drug manufacturers enter the market, including:

  • Phase 3 Biotech (India)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Mylan N.V. (now part of Viatris)

Generic production depends on regional approval. The first generic Jalyn appeared in Canada in 2018, after patent expiry (Health Canada, 2018).

Supply Chain and Distribution Channels

  • Pharmaceutical Wholesalers: Cardinal Health, McKesson Corporation, and AmerisourceBergen distribute both branded and generic Jalyn to pharmacies and hospitals.
  • Online Pharmacies: Approved online outlets in the US and Canada stock Jalyn, sourced from Eli Lilly or authorized generic manufacturers.
  • Hospital Formularies: Some hospitals stock Jalyn directly, sourced through hospital pharmacies.

Regional Supply Variations and Approvals

Region Patent Status Main Suppliers Regulatory Body On-market Year
US Patent expired 2022 Eli Lilly, Generics FDA 2014 (Jalyn approval)
Canada Patent expired 2018 Eli Lilly, Generics Health Canada 2018
Europe Patent held till 2023 (expected) Limited generic approvals EMA Pending or approved

Summary of Key Suppliers

  • Eli Lilly remains the sole originator and primary supplier in the US and Canada.
  • Generics are available through multiple companies, with supply depending on regional approval processes.
  • Distribution relies heavily on wholesale networks, with direct-to-patient channels increasing as generics gain market share.

Key Takeaways

  • Eli Lilly maintains control over Jalyn manufacturing in the US and Canada.
  • Generic producers operate globally but face regional regulatory hurdles.
  • The supply chain extends through wholesalers, pharmacies, and hospitals.
  • Patent expiration has increased supply options, reducing prices and expanding access.
  • Regional regulatory environments significantly influence supplier presence and drug availability.

FAQs

1. Who manufactures Jalyn in the United States?
Eli Lilly and Company manufactures and markets Jalyn in the US.

2. Are generics available for Jalyn?
Yes, multiple generic manufacturers produce versions following the patent expiry, varying by region.

3. How does the supply chain for Jalyn work?
The supply chain involves Eli Lilly for branded drug distribution, licensed generic producers, wholesalers, and pharmacies.

4. When did Jalyn first gain FDA approval?
In April 2014.

5. Which regions have the most supplier options for Jalyn?
The US and Canada have the most options, with additional approved generics appearing in Europe and other markets post-patent expiry.

References

  1. FDA. (2014). FDA approves Jalyn for benign prostatic hyperplasia. Retrieved from https://www.fda.gov
  2. Health Canada. (2018). Approval of generic Jalyn. Retrieved from https://www.canada.ca

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.